首页> 美国卫生研究院文献>Journal for Immunotherapy of Cancer >Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

【2h】

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

机译：在临床前肿瘤模型中将IDO1抑制剂GDC-0919与抗PD-1l阻断剂联合使用相比单独使用抗PD-1l阻断剂具有更高的抗肿瘤免疫力和功效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Journal for Immunotherapy of Cancer
作者
Jessica Spahn; Jing Peng; Edward Lorenzana; David Kan; Thomas Hunsaker; Ehud Segal; Mario Mautino; Erik Brincks; Andrea Pirzkall; Sean Kelley; Sami Mahrus; Liling Liu; Stephanie Dale; Cristine Quiason; Elizabeth Jones; Yichin Liu; Sheerin Latham; Laurent Salphati; Kevin DeMent; Mark Merchant; Georgia Hatzivassiliou;
展开▼
作者单位

展开▼
年(卷),期 2015(3),Suppl 2
年度 2015
页码 P303
总页数 1
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models [J] . Jessica Spahn, Jing Peng, Edward Lorenzana, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：在临床前肿瘤模型中，将IDO1抑制剂GDC-0919与抗PD-1l阻断剂联合使用相比，单独使用抗PD-1l阻断剂具有更高的抗肿瘤免疫力和功效
2. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model [J] . Mony Jyothi Thyagabhavan, Zhang Lixin, Ma Tianzhou, Cancer immunology, immunotherapy : . 2015,第9期

机译：在人类MUC1表达的临床前卵巢癌模型中，抗PD-L1可以延长生存期并触发T细胞，但不会触发体液抗肿瘤免疫反应
3. 151 Allosteric {MEK} inhibitor {BAY} 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer [J] . F. Puehler, A. Scholz, M. Kissel, European Journal of Cancer Supplements . 2010,第7期

机译：151变构 {MEK }抑制剂 {BAY } 86-9766（RDEA119）在肝细胞癌和胰腺癌的临床前模型中显示单一疗法和联合疗法的抗肿瘤功效
4. Combination of angiogenesis inhibitors increases the anti-tumor efficacy of photodynamic therapy in a human bladder tumor xenograft model [C] . Ramaswamy Bhuvaneswari, Yik Yuen Gan, Patricia SP Thong, World congress of the International Photodynamic Association . 2009

机译：血管生成抑制剂的组合增加了光动力疗法在人膀胱肿瘤异种移植模型中的抗肿瘤功效
5. Understanding How Adrenergic Stress Signaling Impacts the Anti-Tumor Immune Response and the Efficacy of Checkpoint Inhibitors in Murine Tumor Models [D] . Bucsek, Mark Joseph. 2019

机译：了解肾上腺素能应激信号如何影响抗肿瘤免疫应答以及检查点抑制剂在鼠肿瘤模型中的疗效
6. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model [O] . Jyothi Thyagabhavan Mony, Lixin Zhang, Tianzhou Ma, -1

机译：在人类MUC1表达的临床前卵巢癌模型中抗PD-L1延长生存期并触发T细胞但不触发体液抗肿瘤免疫反应
7. Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models [O] . 2015

机译：在临床前肿瘤模型中，将IDO1抑制剂GDC-0919与抗PD-1l阻断剂联合使用相比，单独使用抗PD-1l阻断剂具有更高的抗肿瘤免疫力和功效

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

著录项

相似文献

相关主题

期刊订阅